Militia Capital Partners LP Has $3.96 Million Stock Holdings in Medpace Holdings, Inc. $MEDP

Key Points

• Militia Capital Partners LP significantly increased its stake in Medpace Holdings, Inc. by 3,839.4%, making the company its 7th largest position with holdings valued at approximately $3.96 million.
• Medpace reported strong quarterly earnings, with $3.10 earnings per share that exceeded expectations, leading to a revenue increase of 14.2% year-over-year.
• Analysts have mixed views on Medpace, with two rating it as a buy, eleven as a hold, and three as a sell, reflecting a consensus price target of $422.27.

Militia Capital Partners LP raised its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 3,839.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,000 shares of the company's stock after purchasing an additional 12,670 shares during the period. Medpace comprises about 3.1% of Militia Capital Partners LP's portfolio, making the stock its 7th largest holding. Militia Capital Partners LP's holdings in Medpace were worth $3,961,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. increased its stake in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after purchasing an additional 37 shares during the last quarter. Brooklyn Investment Group increased its stake in Medpace by 244.8% during the first quarter. Brooklyn Investment Group now owns 100 shares of the company's stock valued at $30,000 after purchasing an additional 71 shares during the last quarter. Whittier Trust Co. increased its stake in Medpace by 47.3% during the first quarter. Whittier Trust Co. now owns 109 shares of the company's stock valued at $33,000 after purchasing an additional 35 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new stake in Medpace during the first quarter valued at $60,000. Finally, Assetmark Inc. grew its position in shares of Medpace by 24.9% during the first quarter. Assetmark Inc. now owns 216 shares of the company's stock worth $66,000 after acquiring an additional 43 shares during the last quarter. Institutional investors own 77.98% of the company's stock.

Medpace Trading Up 0.4%

MEDP stock traded up $1.84 during midday trading on Wednesday, reaching $492.61. The company had a trading volume of 70,605 shares, compared to its average volume of 439,218. The company has a 50 day moving average of $436.37 and a two-hundred day moving average of $351.59. The company has a market capitalization of $13.84 billion, a P/E ratio of 36.62, a PEG ratio of 3.12 and a beta of 1.44. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $501.30.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, topping analysts' consensus estimates of $3.00 by $0.10. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The business had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. During the same period in the prior year, the business posted $2.75 earnings per share. Medpace's revenue for the quarter was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Mizuho upped their price target on shares of Medpace from $328.00 to $510.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Robert W. Baird upped their price target on shares of Medpace from $313.00 to $490.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 23rd. UBS Group lowered shares of Medpace from a "neutral" rating to a "sell" rating and upped their price target for the stock from $300.00 to $305.00 in a research report on Tuesday, July 29th. Barclays increased their target price on shares of Medpace from $300.00 to $450.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 23rd. Finally, Rothschild Redb lowered shares of Medpace from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, September 3rd. Two equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have assigned a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Reduce" and an average price target of $422.27.

Insider Activity

In other Medpace news, General Counsel Stephen P. Ewald sold 3,000 shares of the stock in a transaction on Monday, July 28th. The shares were sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the transaction, the general counsel directly owned 10,343 shares of the company's stock, valued at $4,654,350. This represents a 22.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Susan E. Burwig sold 10,000 shares of the stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $480.00, for a total transaction of $4,800,000.00. Following the transaction, the vice president directly owned 57,500 shares in the company, valued at $27,600,000. The trade was a 14.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 161,266 shares of company stock valued at $74,111,427. Corporate insiders own 20.30% of the company's stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.